Piet van der Slikke, CEO: 'We are satisfied with our results in the first half of 2016. Our business has shown growth both as a result of the acquisitions in the US and Brazil in 2015 and organically. The recent acquisition of Mutchler in the US and Puerto Rico is an important further step in the execution of our US strategy and our global strategy in pharmaceuticals. In an increasingly uncertain macro-economic environment we continue to focus on executing our strategy and on operational excellence.'
To read the full press release, please click the link
below: